TY  - JOUR
AU  - Antanasković, Ana
AU  - Stević, Ivana
AU  - Gojak, Refet
AU  - Lakić, Dragana
AU  - Janković, Slobodan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5269
AB  - Alpha-mannosidosis is an inherited rare disorder of mannose-containing oligosaccharides metabolism that is currently treated by enzyme replacement therapy (ERT), bone marrow transplantation (BMT), or supportive therapy (ST). However, the relative cost-effectiveness of these treatment options is yet unknown. Our study aimed to compare the cost-effectiveness of the treatment options for mild to moderate alpha-mannosidosis. The study is based on a modeling approach using a Discrete-Event Simulation model to generate and simulate the course of the disease under the influence of each of the treatment options: ERT, BMT, and ST. The model had a lifetime horizon and was made from the perspective of the Serbian Health Insurance Fund. Currently, available causal therapy of mild to moderate alpha-mannosidosis with velmanase alpha enzyme replacement is not cost-effective compared with supportive therapy (ICER = 941,587,152 RSD) or bone marrow transplantation (ICER = −398,412,755 RSD). Bone marrow transplantation can be cost-effective compared to supportive therapy (ICER = 6,032,689 RSD), but only if the willingness-to-pay threshold is increased to 9 gross domestic products (GDP) per capita per QALY gained. According to the current threshold, velmanase-alfa is not cost-effective compared to BMT or ST. To make alfa-mannosidosis therapy widely accessible to patients, criteria for assessing the cost-effectiveness of orphan drugs must include not only the absolute value of ICER but other aspects like equity weightings of QALYs, risk-sharing, reimbursement of severe forms of a disease only, or availability of dedicated funding.
PB  - Taylor and Francis Ltd.
T2  - Biotechnology and Biotechnological Equipment
T1  - Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis
VL  - 37
IS  - 1
DO  - 10.1080/13102818.2023.2271574
ER  - 

@article{
author = "Antanasković, Ana and Stević, Ivana and Gojak, Refet and Lakić, Dragana and Janković, Slobodan",
year = "2023",
abstract = "Alpha-mannosidosis is an inherited rare disorder of mannose-containing oligosaccharides metabolism that is currently treated by enzyme replacement therapy (ERT), bone marrow transplantation (BMT), or supportive therapy (ST). However, the relative cost-effectiveness of these treatment options is yet unknown. Our study aimed to compare the cost-effectiveness of the treatment options for mild to moderate alpha-mannosidosis. The study is based on a modeling approach using a Discrete-Event Simulation model to generate and simulate the course of the disease under the influence of each of the treatment options: ERT, BMT, and ST. The model had a lifetime horizon and was made from the perspective of the Serbian Health Insurance Fund. Currently, available causal therapy of mild to moderate alpha-mannosidosis with velmanase alpha enzyme replacement is not cost-effective compared with supportive therapy (ICER = 941,587,152 RSD) or bone marrow transplantation (ICER = −398,412,755 RSD). Bone marrow transplantation can be cost-effective compared to supportive therapy (ICER = 6,032,689 RSD), but only if the willingness-to-pay threshold is increased to 9 gross domestic products (GDP) per capita per QALY gained. According to the current threshold, velmanase-alfa is not cost-effective compared to BMT or ST. To make alfa-mannosidosis therapy widely accessible to patients, criteria for assessing the cost-effectiveness of orphan drugs must include not only the absolute value of ICER but other aspects like equity weightings of QALYs, risk-sharing, reimbursement of severe forms of a disease only, or availability of dedicated funding.",
publisher = "Taylor and Francis Ltd.",
journal = "Biotechnology and Biotechnological Equipment",
title = "Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis",
volume = "37",
number = "1",
doi = "10.1080/13102818.2023.2271574"
}

Antanasković, A., Stević, I., Gojak, R., Lakić, D.,& Janković, S.. (2023). Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis. in Biotechnology and Biotechnological Equipment
Taylor and Francis Ltd.., 37(1).
https://doi.org/10.1080/13102818.2023.2271574

Antanasković A, Stević I, Gojak R, Lakić D, Janković S. Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis. in Biotechnology and Biotechnological Equipment. 2023;37(1).
doi:10.1080/13102818.2023.2271574 .

Antanasković, Ana, Stević, Ivana, Gojak, Refet, Lakić, Dragana, Janković, Slobodan, "Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis" in Biotechnology and Biotechnological Equipment, 37, no. 1 (2023),
https://doi.org/10.1080/13102818.2023.2271574 . .

TY  - JOUR
AU  - Janković, Slobodan
AU  - Bogavac-Stanojević, Nataša
AU  - Mikulić, Iva
AU  - Izetbegović, Sebija
AU  - Iličković, Ivana
AU  - Krajnović, Dušanka
AU  - Suljic Mehmedika, Enra
AU  - Gojak, Refet
AU  - Mehičević, Admir
AU  - Gazibera, Belma
AU  - Mahmutbegović, Nevena
AU  - Stojadinović, Milorad
AU  - Janković, Nikola
AU  - Miljković, Sanja
AU  - Popović, Slađana
AU  - Blidarević, Bojan
AU  - Mugoša, Snežana
AU  - Đorđević, Zorana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3994
AB  - Prenos instrumentov za merjenje kakovosti življenja, razvitih v nekaterih, večinoma razvitejših delih sveta, zahteva transkulturno validacijo. Kljub temu tovrstni instrumenti običajno ne zajemajo regionalno specifičnih vidikov kakovosti življenja, povezanih z zdravjem. Namen študije je bil razviti in potrditi zanesljiv vprašalnik v srbskem, hrvaškem, bosansko-hrvaško-srbskem in črnogorskem jeziku, primeren za merjenje kakovosti življenja, povezanega z zdravjem odraslih.
AB  - Translations of instruments for measuring quality of life developed in certain, mostly more
developed, parts of the world usually do not cover regionally specific aspects of health-related quality of life,
even after transcultural validation. The aim of this study was to develop and validate a reliable questionnaire
in Serbian, Croatian, Bosnian, and Montenegrin languages suitable for measuring health-related quality of life
in adults.
PB  - Sciendo
T2  - Zdravstveno varstvo
T1  - Vprašalnik za merjenje kakovosti življenja, povezanega z zdravjem
T1  - A questionnaire for rating health-related quality of life
VL  - 60
IS  - 4
SP  - 260
EP  - 268
DO  - 10.2478/sjph-2021-0035
ER  - 

@article{
author = "Janković, Slobodan and Bogavac-Stanojević, Nataša and Mikulić, Iva and Izetbegović, Sebija and Iličković, Ivana and Krajnović, Dušanka and Suljic Mehmedika, Enra and Gojak, Refet and Mehičević, Admir and Gazibera, Belma and Mahmutbegović, Nevena and Stojadinović, Milorad and Janković, Nikola and Miljković, Sanja and Popović, Slađana and Blidarević, Bojan and Mugoša, Snežana and Đorđević, Zorana",
year = "2021",
abstract = "Prenos instrumentov za merjenje kakovosti življenja, razvitih v nekaterih, večinoma razvitejših delih sveta, zahteva transkulturno validacijo. Kljub temu tovrstni instrumenti običajno ne zajemajo regionalno specifičnih vidikov kakovosti življenja, povezanih z zdravjem. Namen študije je bil razviti in potrditi zanesljiv vprašalnik v srbskem, hrvaškem, bosansko-hrvaško-srbskem in črnogorskem jeziku, primeren za merjenje kakovosti življenja, povezanega z zdravjem odraslih., Translations of instruments for measuring quality of life developed in certain, mostly more
developed, parts of the world usually do not cover regionally specific aspects of health-related quality of life,
even after transcultural validation. The aim of this study was to develop and validate a reliable questionnaire
in Serbian, Croatian, Bosnian, and Montenegrin languages suitable for measuring health-related quality of life
in adults.",
publisher = "Sciendo",
journal = "Zdravstveno varstvo",
title = "Vprašalnik za merjenje kakovosti življenja, povezanega z zdravjem, A questionnaire for rating health-related quality of life",
volume = "60",
number = "4",
pages = "260-268",
doi = "10.2478/sjph-2021-0035"
}

Janković, S., Bogavac-Stanojević, N., Mikulić, I., Izetbegović, S., Iličković, I., Krajnović, D., Suljic Mehmedika, E., Gojak, R., Mehičević, A., Gazibera, B., Mahmutbegović, N., Stojadinović, M., Janković, N., Miljković, S., Popović, S., Blidarević, B., Mugoša, S.,& Đorđević, Z.. (2021). Vprašalnik za merjenje kakovosti življenja, povezanega z zdravjem. in Zdravstveno varstvo
Sciendo., 60(4), 260-268.
https://doi.org/10.2478/sjph-2021-0035

Janković S, Bogavac-Stanojević N, Mikulić I, Izetbegović S, Iličković I, Krajnović D, Suljic Mehmedika E, Gojak R, Mehičević A, Gazibera B, Mahmutbegović N, Stojadinović M, Janković N, Miljković S, Popović S, Blidarević B, Mugoša S, Đorđević Z. Vprašalnik za merjenje kakovosti življenja, povezanega z zdravjem. in Zdravstveno varstvo. 2021;60(4):260-268.
doi:10.2478/sjph-2021-0035 .

Janković, Slobodan, Bogavac-Stanojević, Nataša, Mikulić, Iva, Izetbegović, Sebija, Iličković, Ivana, Krajnović, Dušanka, Suljic Mehmedika, Enra, Gojak, Refet, Mehičević, Admir, Gazibera, Belma, Mahmutbegović, Nevena, Stojadinović, Milorad, Janković, Nikola, Miljković, Sanja, Popović, Slađana, Blidarević, Bojan, Mugoša, Snežana, Đorđević, Zorana, "Vprašalnik za merjenje kakovosti življenja, povezanega z zdravjem" in Zdravstveno varstvo, 60, no. 4 (2021):260-268,
https://doi.org/10.2478/sjph-2021-0035 . .